Treatment of Disseminated Intravascular Coagulation and Its Prodromal Stage with Gabaxate Mesilate (FOY): A Multi-Center Trial

Abstract
One hundred and ninety-one patients with disseminated intravascular coagulation syndrome (DIC) or its prodromal stage (preDIC) were treated with only gabaxate mesilate (FOY®) (group G) or a combination of gabaxate and un-fractionated heparin (group GH), and the efficacy of gabaxate was evaluated in a multicenter study. Following the treatment, the mean DIC score, which was evaluated on the basis of clinical symptoms and hemostatic parameters, decreased significantly to 5.58 ± 3.48 from 6.75 ± 3.14 in group G (p

This publication has 0 references indexed in Scilit: